Sign In
Buy ABBV
$250.88
-6.74 (-2.61%)
At Close: Jul 31, 2026
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
08:00am, Friday, 26'th Jun 2026
NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens.
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
04:55pm, Thursday, 25'th Jun 2026
AbbVie is aggressively expanding its pipeline to offset the impact of biosimilar competition for its top-selling drugs. Pfizer is utilizing substantial capital for acquisitions to diversify its revenu
Is AbbVie a Buy After Its Purchase of Apogee?
09:53am, Thursday, 25'th Jun 2026
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
08:15am, Thursday, 25'th Jun 2026
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical asse
Why I Can't Stop Buying This Unstoppable Dividend Juggernaut
04:33pm, Wednesday, 24'th Jun 2026
I hit the buy button on AbbVie (NYSE:ABBV | ABBV Price Prediction) again last week, and I will hit it again the next time June's macro noise hands me a discount.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
AbbVie's $11 Billion Immunology Bet
12:51pm, Wednesday, 24'th Jun 2026
In this week's edition of InnovationRx, we look at AbbVie's new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more. To get
AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis
10:36am, Wednesday, 24'th Jun 2026
ABBV gains EU approval for Skyrizi in pediatric plaque psoriasis, expanding reach in younger patients with a new weight-based dosing option.
64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
10:02am, Wednesday, 24'th Jun 2026
At 64, with $1.1 million in a Traditional IRA, tax-deferred cash flow is the point. With the 10-year Treasury at 4.50% and the 30-year at 4.94%, dividend yields have to earn their seat. The 10-year ha
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
08:00am, Wednesday, 24'th Jun 2026
250 Women Entrepreneurs Have Been Selected to Join a Multi-Week Skill-Building, Mentorship, and Networking Program BOTOX® Cosmetic Will Award 20 Participants With $20,000 Grants Each to Help Take The
After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching
07:55am, Wednesday, 24'th Jun 2026
Biotech M&A is back in the spotlight. Big Pharma faces patent cliffs over the next several years, and recent dealmaking, including the AbbVie (NYSE: ABBV | ABBV Price Prediction) acquisition of Apogee
AbbVie's Costly Apogee Acquisition Has Long-Term Upside: Analyst
01:11pm, Tuesday, 23'rd Jun 2026
On Monday, biopharmaceutical giant AbbVie Inc. (NYSE:ABBV) agreed to acquire Apogee Therapeutics Inc. (NASDAQ:APGE) in a cash deal valued at approximately $10.9 billion.
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
11:50am, Tuesday, 23'rd Jun 2026
AbbVie shares jump after its $10.9B Apogee deal adds late-stage eczema and respiratory candidates, deepening its immunology pipeline.
Nova Minerals redomiciles to US as Alaska gold and antimony work accelerates
08:23am, Tuesday, 23'rd Jun 2026
Nova Minerals Corp (ASX:NVA, NYSE-A:NVA, FRA:QM30) has completed its redomicile to the United States and started key 2026 field work at its Estelle Gold and...
